Trial Profile
Treprostinil for Untreated Symptomatic PAH Trial: A 12-Week Multicenter Randomized Double-Blind Placebo-Controlled Trial of the Safety and Efficacy of Intravenous Remodulin in Patients in India With Pulmonary Arterial Hypertension
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 25 Jun 2014
Price :
$35
*
At a glance
- Drugs Treprostinil (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms TRUST-1
- Sponsors United Therapeutics Corporation
- 25 Jun 2014 New trial record